Form 8-K 2013 Annual Meeting Voting Results
 
 
 
 
 


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

__________________

FORM 8-K
__________________

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): May 9, 2013


Lexicon Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)


Delaware
000-30111
76-0474169
(State or other jurisdiction of
incorporation or organization)
(Commission File Number)
(I.R.S. Employer
Identification Number)


8800 Technology Forest Place
The Woodlands, Texas 77381
(Address of principal executive
offices and Zip Code)


(281) 863-3000
(Registrant's telephone number,
including area code)


Check the appropriate box below if the Form 8‑K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a‑12 under the Exchange Act (17 CFR 240.14a‑12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d‑2(b))
o
Pre-commencement communications pursuant to Rule 13e‑4(c) under the Exchange Act (17 CFR 240.13e‑4(c))
 
 
 
 
 



Item 5.07
Submission of Matters to a Vote of Security Holders

Our annual meeting of stockholders was held on May 9, 2013 to consider and vote on the following proposals. The voting results with respect to each matter are set forth below:
(1)
Election of Class I Directors:
 
 
 
 
Name of Director
For
Withheld
Broker 
Non-Votes
 
Raymond Debbane
431,610,315
13,024,381
31,763,494
 
Robert J. Lefkowitz, M.D.
427,757,618
16,877,078
31,763,494
 
Alan S. Nies, M.D.
412,179,562
32,455,134
31,763,494
 
 
For
Against
Abstain
Broker Non-Votes
(2)
Advisory vote to approve the compensation paid to our named executive officers
428,399,216
14,092,004
2,143,476
31,763,494
 
 
For
Against
Abstain
Broker Non-Votes
(3)
Ratification and approval of the appointment of Ernst & Young LLP as our independent auditors for the fiscal year ending December 31, 2013
474,592,854
1,045,678
759,658
—






Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 
Lexicon Pharmaceuticals, Inc.
 
 
 
 
 
 
Date: May 9, 2013
By:
/s/ Brian T. Crum
 
 
Brian T. Crum
 
 
Vice President and General Counsel